ReproCell Saham

ReproCell Kas & Setara Kas

Kas & Investasi Jangka Pendek dari ReproCell (4978.T) pada 13 Agu 2026 adalah 3,94 miliar JPY. Tahun sebelumnya, Kas & Investasi Jangka Pendek adalah 6,57 miliar JPY — perubahan sebesar -39,98% (lebih rendah).

Kas & Setara Kas

3,94 miliarJPY

YoY

-39,98%

Terakhir Diperbarui:

Kas & Investasi Jangka Pendek dari ReproCell adalah 2026 3,94 miliar JPY. Kas & Investasi Jangka Pendek dari ReproCell adalah 2025 6,57 miliar JPY. Menurun -39,98% lebih rendah dibandingkan dengan tahun sebelumnya.
Access this data via the Eulerpool API

ReproCell Analisis saham

Apa yang dilakukan ReproCell? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell adalah salah satu perusahaan paling populer di Eulerpool.

Pertanyaan yang Sering Diajukan tentang saham ReproCell

Kas & Investasi Jangka Pendek ReproCell adalah 3,94 miliar JPY pada tahun 2026.

Kas & Investasi Jangka Pendek dari ReproCell berubah dari 6,57 miliar JPY menjadi 3,94 miliar JPY, mewakili perubahan -39,98%. Nilainya lebih rendah daripada tahun sebelumnya.

Di Eulerpool Anda dapat menemukan perkembangan historis lengkap Kas & Investasi Jangka Pendek ReproCell sejak 2006 – dengan nilai tahunan, bagan, dan analisis detail.

Kas dan setara kas mewakili aset paling likuid di neraca, tersedia untuk penggunaan segera atau kewajiban jangka pendek.

JPY Kas & Investasi Jangka Pendek adalah faktor kunci bagi investor. Perubahan metrik ini dapat menunjukkan fundamental yang membaik atau memburuk, secara langsung memengaruhi harga saham. Di Eulerpool, Anda dapat melacak ReproCell Kas & Investasi Jangka Pendek secara historis dan real-time.

Access this data via the Eulerpool API

Neraca — ReproCell

Semua Metrik Kunci — ReproCell